유방암 스크리닝 시장 : 기술, 제품, 최종 사용자별 - 세계 전망(2025-2030년)

The Breast Cancer Screening Market was valued at USD 5.01 billion in 2023, expected to reach USD 5.31 billion in 2024, and is projected to grow at a CAGR of 6.72%, to USD 7.90 billion by 2030.

Breast cancer screening involves medical tests designed to detect breast cancer at an early stage before any symptoms appear, primarily through methods like mammograms, ultrasound, and MRI. The necessity of breast cancer screening is underscored by its potential to reduce mortality rates through early detection, which improves treatment efficacy. Its applications span hospitals, diagnostic laboratories, and specialty clinics, with end-use mainly among women aged 40 and above, though increasing accessibility extends these services to younger women due to rising awareness. Key market growth factors include advancements in screening technology, such as 3D mammography and AI-enhanced imaging, along with heightened awareness and female healthcare initiatives globally. Moreover, supportive governmental policies and improved healthcare infrastructure in emerging markets present substantial growth potential. However, challenges remain, including disparities in access to care, particularly in low-income regions, and the ongoing debate about the potential risks of overdiagnosis or false positives, which may undermine screening uptake.

Opportunities for business growth lie in developing cost-effective, portable screening devices and AI tools that enhance imaging accuracy and reduce operational time. Expansion into untapped markets with tailored strategies to improve accessibility and awareness could yield significant dividends. Research into personalized screening approaches, considering genetic and lifestyle factors, might enhance effectiveness and acceptance. The breast cancer screening market is dynamic, driven by technological innovation and public health policies, but it requires navigating regulatory landscapes and addressing socio-economic barriers. The nature of this market is highly competitive, with established healthcare giants and boutique firms vying for market presence, largely dictated by technological prowess and strategic alliances. Companies are recommended to prioritize investment in R&D for cutting-edge technologies, strategically collaborate with governmental agencies for better reach, and actively engage in community outreach programs to educate and encourage regular screening adherence, ensuring holistic market penetration and sustenance.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Breast Cancer Screening Market

The Breast Cancer Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing cases of cancer in women globally
  • Government health campaign to raise disease awareness
  • Significant adoption of MRI techniques for screening and monitoring.
• Market Restraints
  • Breast cancer screening device recalls
• Market Opportunities
  • Emergence of AI-supported 3D mammogram screening for cancer screening
  • Adoption of advanced Immunotherapy
• Market Challenges
  • Potential risk of false results

Porter's Five Forces: A Strategic Tool for Navigating the Breast Cancer Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Breast Cancer Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Breast Cancer Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Breast Cancer Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Breast Cancer Screening Market

A detailed market share analysis in the Breast Cancer Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Breast Cancer Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Breast Cancer Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Breast Cancer Screening Market

A strategic analysis of the Breast Cancer Screening Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Screening Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca plc, Bayer AG, Becton, Dickinson and Company, Carestream Health, Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Fujifilm Holdings Corporation, GE HealthCare Technologies Inc., GlaxoSmithKline plc, Hologic, Inc., Koning Health, Koninklijke Philips N.V., Myriad Genetics, Inc., NanoString Technologies, Inc., NIRAMAI Health Analytix Private Limited, Novartis AG, Oncocyte Corporation, OncoStem Diagnostics Pvt. Ltd, Pfizer Inc., Prelude Corporation, Quest Diagnostics Incorporated, Siemens Healthineers AG, Syantra Inc., and Vayyar Imaging, Ltd..

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Ionizing Breast Imaging Technologies and Non-ionizing Breast Imaging Technologies. The Ionizing Breast Imaging Technologies is further studied across 3D Breast Tomosynthesis, Analog Mammography, Cone-Beam Computed Tomography (CBCT), Contrast-Enhanced Mammography (CEM), Full-Field Digital Mammography (FFDM), Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI), Positron Emission Mammography (PEM), and Positron Emission Tomography and Computed Tomography (PET-CT). The Non-ionizing Breast Imaging Technologies is further studied across Automated Whole-Breast Ultrasound (AWBU), Breast MRI, Breast Thermography, Breast Ultrasound, Electric Impedance Tomography, and Optical Imaging.
• Based on Product, market is studied across Accessories, Breast Imaging Systems, and Software & Services.
• Based on End User, market is studied across Breast Care Centers, Diagnostic Imaging Centers, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing cases of cancer in women globally
    • 5.1.1.2. Government health campaign to raise disease awareness
    • 5.1.1.3. Significant adoption of MRI techniques for screening and monitoring.
  • 5.1.2. Restraints
    • 5.1.2.1. Breast cancer screening device recalls
  • 5.1.3. Opportunities
    • 5.1.3.1. Emergence of AI-supported 3D mammogram screening for cancer screening
    • 5.1.3.2. Adoption of advanced Immunotherapy
  • 5.1.4. Challenges
    • 5.1.4.1. Potential risk of false results
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Breast Cancer Screening Market, by Technology

• 6.1. Introduction
• 6.2. Ionizing Breast Imaging Technologies
  • 6.2.1. 3D Breast Tomosynthesis
  • 6.2.2. Analog Mammography
  • 6.2.3. Cone-Beam Computed Tomography (CBCT)
  • 6.2.4. Contrast-Enhanced Mammography (CEM)
  • 6.2.5. Full-Field Digital Mammography (FFDM)
  • 6.2.6. Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI)
  • 6.2.7. Positron Emission Mammography (PEM)
  • 6.2.8. Positron Emission Tomography and Computed Tomography (PET-CT)
• 6.3. Non-ionizing Breast Imaging Technologies
  • 6.3.1. Automated Whole-Breast Ultrasound (AWBU)
  • 6.3.2. Breast MRI
  • 6.3.3. Breast Thermography
  • 6.3.4. Breast Ultrasound
  • 6.3.5. Electric Impedance Tomography
  • 6.3.6. Optical Imaging

7. Breast Cancer Screening Market, by Product

• 7.1. Introduction
• 7.2. Accessories
• 7.3. Breast Imaging Systems
• 7.4. Software & Services

8. Breast Cancer Screening Market, by End User

• 8.1. Introduction
• 8.2. Breast Care Centers
• 8.3. Diagnostic Imaging Centers
• 8.4. Hospitals & Clinics

9. Americas Breast Cancer Screening Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Breast Cancer Screening Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Breast Cancer Screening Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AstraZeneca plc
• 2. Bayer AG
• 3. Becton, Dickinson and Company
• 4. Carestream Health, Inc.
• 5. Danaher Corporation
• 6. Exact Sciences Corporation
• 7. F. Hoffmann-La Roche Ltd
• 8. Fujifilm Holdings Corporation
• 9. GE HealthCare Technologies Inc.
• 10. GlaxoSmithKline plc
• 11. Hologic, Inc.
• 12. Koning Health
• 13. Koninklijke Philips N.V.
• 14. Myriad Genetics, Inc.
• 15. NanoString Technologies, Inc.
• 16. NIRAMAI Health Analytix Private Limited
• 17. Novartis AG
• 18. Oncocyte Corporation
• 19. OncoStem Diagnostics Pvt. Ltd
• 20. Pfizer Inc.
• 21. Prelude Corporation
• 22. Quest Diagnostics Incorporated
• 23. Siemens Healthineers AG
• 24. Syantra Inc.
• 25. Vayyar Imaging, Ltd.